-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Reports Early Phase 1 Clinical Activity for CAR-T Candidate in Multiple Myeloma

PUBT·11/12/2026 22:01:58
Listen to the news
Tempest Reports Early Phase 1 Clinical Activity for CAR-T Candidate in Multiple Myeloma
  • Tempest Therapeutics today exercised its option to license Senlang's CD7-targeted lentiviral CAR-T platform, securing exclusive global rights outside China.
  • Lead candidate TPST-4903 targets BCMA/GPRC5D in the DELIVER-1 Phase 1 trial, which treated 13 patients with relapsed or refractory multiple myeloma.
  • The trial includes heavily pretreated patients with extramedullary disease or prior BCMA-targeted CAR-T therapy.
  • Preliminary clinical activity and tolerability observations supported the licensing decision, but longer follow-up is needed to assess benefits and risks.
  • Detailed results are planned for presentation at a major scientific conference.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-118986), on November 12, 2026, and is solely responsible for the information contained therein.